Financials in USD. Standardized financial statements.
A compact view of how Ascletis Pharma Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.98M | $1.28M | $56.60M | $54.09M | $76.88M | $35.00M | $173.44M | $166.32M | $53.20M | $32.98M |
| Revenue Growth? | +54.0% | -97.7% | +4.6% | -29.6% | +119.6% | -79.8% | +4.3% | +212.6% | +61.3% | 0.0% |
| Cost of Revenue? | $18.62M | $548,000 | $30.61M | $78.78M | $37.70M | $58.50M | $49.16M | $12.38M | $0 | $0 |
| Gross Profit? | -$16.65M | $735,000 | $25.99M | -$24.69M | $39.17M | -$23.50M | $124.28M | $153.95M | $53.20M | $32.98M |
| Gross Margin? | -842.7% | +57.3% | +45.9% | -45.6% | +51.0% | -67.1% | +71.7% | +92.6% | +100.0% | +100.0% |
| Operating Expenses? | $454.63M | $296.15M | $326.20M | $319.29M | $264.14M | $129.44M | $225.56M | $287.87M | $151.80M | $75.73M |
| Operating Income? | -$471.27M | -$295.42M | -$300.21M | -$343.98M | -$224.97M | -$217.11M | -$36.44M | -$133.93M | -$98.60M | -$42.75M |
| EBITDA? | -$454.11M | -$390.45M | -$126.09M | -$284.50M | -$169.35M | -$181.94M | -$73.64M | -$131.45M | -$93.13M | -$40.28M |
| Income Before Tax | -$350.10M | -$300.94M | -$144.72M | -$314.84M | -$199.02M | -$209.24M | -$95.97M | -$19.87M | -$80.44M | -$31.87M |
| Income Tax Expense | -$492,936 | $0 | $0 | $0 | $0 | $0 | $0 | -$125,000 | $6.49M | $0 |
| Net Income? | -$350.59M | -$300.94M | -$144.72M | -$314.84M | -$199.02M | -$209.24M | -$95.97M | -$7.26M | -$53.94M | -$26.81M |
| EPS? | $-0.36 | $-0.30 | $-0.13 | $-0.29 | $-0.18 | $-0.20 | $-0.15 | $-0.01 | $-0.09 | $-0.02 |
| Diluted EPS? | $-0.36 | $-0.30 | $-0.13 | $-0.29 | $-0.18 | $-0.20 | $-0.15 | $-0.01 | $-0.09 | $-0.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality